ERIS · Health Care · 2026-08-21

Eris Lifesciences Ltd

Stage 1 · wk 12In scan: Breakout WatchMARKET: BULL RISING · 2026-08-21
₹1,328.2
+0.17% today
₹18,407 Cr · Mid cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions. It offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.

Visit company website →
P/E (TTM)
29.9
Forward 21.7
Earnings Growth (YoY)
+200.0%
Revenue +7.1%
ROE
+18.1%
Profit margin +19.9%
Dividend Yield
1.06%
P/B 6.0
vs 52W High
-26.3%
₹1,271 lo₹1,801.7 hi
26.3% below 52W high — far from high
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 12
1w13w26w
Week 12 — base building
How long this stock has been basing. Longer bases can produce stronger breakouts — but don't anticipate, wait for the breakout.
vs 200 DMA
-7.3%
200 DMA: ₹1,432.2 · sloping down
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
0.67x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
↓
MA20 rolling over · -3.2% vs MA50 +0.0%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
Sector has 84 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Industry has 58 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-26 → 2026-08-21
S2 31w
S2 33w
S2 26w
S4 23w
2023-05-262026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 1w → S1 6w → S2 31w → S3 13w → S4 3w → S1 1w → S2 33w → S3 10w → S2 26w → S3 12w → S4 23w → S1 12w current
Total tracked: 169 weeks across 12 stage runs.
1M
-4.8%
3M
-1.2%
6M
-2.7%
YTD
-13.0%
1Y
-20.9%
Scan Membership
Breakout Watch
Latest: 2025-04-03
2 appearances in last 60 days. First seen: 2024-06-06.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S1
Wk 12 · Vol —x
2026-08-20S1
Wk 12 · Vol —x
2026-08-19S1
Wk 12 · Vol —x
2026-08-18S1
Wk 11 · Vol —x
2026-08-17S1
Wk 11 · Vol —x
2026-08-14S1
Wk 11 · Vol —x
2026-08-13S1
Wk 11 · Vol —x
2026-08-12S1
Wk 11 · Vol —x
2026-08-11S1
Wk 10 · Vol —x
2026-08-10S1
Wk 10 · Vol —x
2026-08-07S1
Wk 10 · Vol —x
2026-08-06S1
Wk 10 · Vol —x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹1,410.1
200 DMA
₹1,432.2
52W High
₹1,801.7
52W Low
₹1,271
5D Low
₹1,326
Resistance levels (recent highs)
20d High
₹1,426.5
60d High
₹1,488.4
120d High
₹1,488.4
250d High
₹1,801.7
Next resistance
+7.4%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.